In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...
Diffuse large B-cell lymphoma is a common type of non-Hodgkin’s lymphoma that also has a high rate of relapse. Common signs of a relapse include lymph node swelling, as well as the development of “B ...
– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...
People with DLBCL or high-grade B-cell lymphoma may be hospitalized after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems. People with FL ...
Morning Overview on MSN
A drug hit its goal against an aggressive lymphoma in a late-stage trial
Patients with relapsed or refractory diffuse large B-cell lymphoma, one of the fastest-growing blood cancers, gained a new ...
Company Announcement Topline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Jeremy S. Abramson, MD, discusses 2-year results from the phase 3 STARGLO trial, which ...
"We found that older age, early relapse, and noncurative treatments were significantly associated with inferior outcomes at a population level." — Inna Y. Gong, MD, PhD, hematologist in the Division ...
This multicenter retrospective cohort study included 516 patients age ≥14 years diagnosed with DLBCL between January 2016 and December 2023 at two tertiary hospitals in Saudi Arabia. Data on ...
Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...
A Northwestern Medicine study has uncovered new insights that may aid in understanding and potentially treating one of the most common and aggressive forms of non-Hodgkin lymphoma, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results